Clinical Trial Detail

NCT ID NCT04016116
Title Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health
Indications

myelodysplastic/myeloproliferative neoplasm

chronic myelomonocytic leukemia

myeloproliferative neoplasm

Hodgkin's lymphoma

Therapies

Pembrolizumab + Ruxolitinib

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.